The FDA has approved BioMarin's BRINEURA® (cerliponase alfa) for treating children under 3 years old with CLN2 disease.

IASO Bio Receives NMPA Clearance for IASO-782 IND Application to Address Systemic Lupus Erythematosus (SLE).

Nkarta Reveals Start of Clinical Trial Led by Investigators for NKX019 in Treating Systemic Lupus Erythematosus.

Inimmune reports initial cancer patient treated in a phase 1 trial with its new TLR7/8 agonist immunotherapy, INI-4001.

Transposon Reports Conclusive Data from Phase 2 Trial of TPN-101 Targeting C9orf72-Linked ALS and/or Frontotemporal Dementia.

Sage Therapeutics and Biogen Reveal Key Findings from Phase 2 KINETIC 2 Trial of SAGE-324 (BIIB124) for Essential Tremor Treatment.

Pfizer Inc. revealed encouraging topline outcomes from the Phase 3 AFFINE trial, which assesses giroctocogene fitelparvovec.

This trial aims to assess the efficacy and safety of petosemtamab, a Biclonics targeting EGFR and LGR5.

Rhythm Pharmaceuticals Begins Dosing First Patients in Phase 2 Trial for Oral MC4R Agonist LB54640 Targeting Hypothalamic Obesity.

Enlivex Receives Regulatory Authorization For The Initiation Of A Phase I Clinical Trial To Evaluate Allocetra In Patients With Psoriatic Arthritis.

OSE Immunotherapeutics Reports Promising Phase 2 Trial Outcomes for Lusvertikimab in Ulcerative Colitis Treatment.

IASO Biotechnology announced that the FDA has approved its application for a new drug, Equecabtagene Autoleucel (Eque-cel), a fully human anti-BCMA CAR T cell therapy.